CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 98 enrolled
Drug / intervention
Bupivacaine HCl +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00485433
NCT00485433Phase 2Completed

A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair.

Pacira Pharmaceuticals, Inc·interventional·Posted Jun 13, 2007·Updated Mar 2, 2021

In Brief

A Phase 2 clinical trial evaluating Bupivacaine HCl and SKY0402 for Postoperative Pain. Completed, enrolled 98 participants across 7 sites.

Detailed Summary

The purpose of this study is to evaluate three dose levels of SKY0402 compared with 105 mg of bupivacaine HCl.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 13, 2007
Enrollment StartJun 1, 2007
Primary CompletionDec 1, 2007
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 19.1 years ago

Interventions

Bupivacaine HCldrug

Bupivacaine HCl given during hernia repair

SKY0402drug

SKY0402 given during hernia repair